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Aims The type 2 diabetic heart oxidizes more fat and less glucose, which can impair metabolic flexibility and function.
Increased sarcolemmal fatty acid translocase (FAT/CD36) imports more fatty acid into the diabetic myocardium,
feeding increased fatty acid oxidation and elevated lipid deposition. Unlike other metabolic modulators that target
mitochondrial fatty acid oxidation, we proposed that pharmacologically inhibiting fatty acid uptake, as the primary
step in the pathway, would provide an alternative mechanism to rebalance metabolism and prevent lipid accumula-




Hearts from type 2 diabetic and control male Wistar rats were perfused in normoxia, hypoxia and reoxygenation,
with the FAT/CD36 inhibitor sulfo-N-succinimidyl oleate (SSO) infused 4 min before hypoxia. SSO infusion into dia-
betic hearts decreased the fatty acid oxidation rate by 29% and myocardial triglyceride concentration by 48% com-
pared with untreated diabetic hearts, restoring fatty acid metabolism to control levels following hypoxia-
reoxygenation. SSO infusion increased the glycolytic rate by 46% in diabetic hearts during hypoxia, increased pyru-
vate dehydrogenase activity by 53% and decreased lactate efflux rate by 56% compared with untreated diabetic
hearts during reoxygenation. In addition, SSO treatment of diabetic hearts increased intermediates within the se-
cond span of the Krebs cycle, namely fumarate, oxaloacetate, and the FAD total pool. The cardiac dysfunction in
diabetic hearts following decreased oxygen availability was prevented by SSO-infusion prior to the hypoxic stress.
Infusing SSO into diabetic hearts increased rate pressure product by 60% during hypoxia and by 32% following
reoxygenation, restoring function to control levels.
....................................................................................................................................................................................................
Conclusions Diabetic hearts have limited metabolic flexibility and cardiac dysfunction when stressed, which can be rapidly recti-
fied by reducing fatty acid uptake with the FAT/CD36 inhibitor, SSO. This novel therapeutic approach not only re-
duces fat oxidation but also lipotoxicity, by targeting the primary step in the fatty acid metabolism pathway.
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To power contraction the heart requires a constant supply of ATP,
which can be obtained from a range of metabolic fuels. Metabolism of
fatty acids produces more ATP per carbon atom but requires more oxy-
gen per ATP generated, when compared with glucose. In type 2 diabetes,
the heart becomes metabolically abnormal, oxidizing more fatty acids,
and less glucose to meet its energy requirements, and this is associated
with higher myocardial oxygen consumption.1–7 The primary step in
myocardial fatty acid metabolism is fatty acid import into the cardiomyo-
cyte, which is regulated by a family of sarcolemmal fatty acid trans-
porters. Fatty acid translocase (FAT/CD36), the predominant fatty acid
transporter, is increased in diabetes,8 consequently more lipid is im-
ported into the diabetic heart fuelling increased fatty acid oxidation, lipid
storage and, via the Randle effect, suppressing glucose metabolism.9,10
Strategies that modify fatty acid metabolism are of great interest for
the diabetic heart. Compounds such as ranolazine, etomoxir, perhexi-
line, and trimetazidine, which target mitochondrial fatty acid oxidation,
have been investigated predominantly in heart failure and angina.11–15
However, one concern with these mitochondrial fatty acid oxidation in-
hibitors is that entry of fat into the cardiomyocyte can still continue, and
additional fat may accumulate as lipid within the cytosol, as reported in
diabetic rats following chronic etomoxir treatment.16 Thus, a better ap-
proach would be to block fatty acid metabolism at its primary point, at
the level of the sarcolemmal fatty acid uptake, by inhibiting FAT/CD36.
Genetic studies with FAT/CD36-deficient mice showed particular bene-
fit when crossed with PPARa-overexpressing mice prone to lipotoxic
cardiomyopathy, as loss of FAT/CD36 reduced lipid accumulation and
reversed contractile dysfunction.17 However, to exploit this genetic
knowledge, therapeutic strategies that pharmacologically inhibit FAT/
CD36 are needed.
Metabolic dysfunction in diabetes is regulated by complex mechan-
isms relating to increased fatty acid availability and insulin resistance.
Metabolic changes in the diabetic heart become of greater consequence
under conditions of cardiac stress, e.g. when oxygen is restricted.
Published data suggest that the diabetic heart has limited metabolic flexi-
bility to change metabolism in response to stimuli,18,19 and decreased
mitochondrial energetics in response to anoxia.20,21 To acutely adapt
to low oxygen availability the heart must downregulate fatty acid metab-
olism and increase anaerobic glycolysis, mediated in part by AMP-acti-
vated protein kinase (AMPK) activation.22 Interestingly, patients with
type 2 diabetes have a number of hypoxia-associated complications, re-
sulting in the heart being exposed, locally or systemically, to reduced
oxygen supply.23–25 Therefore, understanding whether metabolic flexi-
bility in diabetes in response to hypoxic stress is abnormal, and if it can
be reinstated by pharmacological agents that suppress fatty acid uptake,
is of interest.
Given the accessible location of FAT/CD36 on the extracellular sur-
face of the cardiomyocyte, and its elevated sarcolemmal localization in
the diabetic heart, FAT/CD36 may be an attractive target for metabolic
intervention, as it may simultaneously reduce both fatty acid oxidation
and lipid deposition. In this study, we investigate the FAT/CD36 inhibitor,
sulfo-N-succinimidyl oleate (SSO) as a metabolic modulator, to study its
effects in the intact heart of the type 2 diabetic rat. We questioned
whether inhibition of FAT/CD36 using SSO may provide a novel
pharmacological way to improve metabolism and function of the diabetic
heart challenged by hypoxic stress.
2. Methods
2.1 In vivo rat model of type 2 diabetes
Male Wistar rats (n= 71, starting body weight 250g) were obtained
from a commercial breeder (Harlan, UK). This investigation conformed
to the United Kingdom Home Office guidelines under The Animal
(Scientific Procedures) Act, 1986, and was approved by the University of
Oxford local ethics committee.
Control rats were fed for 42 days on a standard chow diet (Harlan
Laboratories). Type 2 diabetes was induced in rats by feeding a high-fat
diet (60% calories from fat, Special Diet Services) for 42 days and, on day
14, a single low dose intraperitoneal injection of streptozotocin (STZ,
25 mg/kg bodyweight, in citrate buffer, pH 4)7,26–28 was given. We have
previously demonstrated that it is the combination of high-fat diet and
low dose STZ that induces type 2 diabetes,27 as low dose STZ alone
does not impair insulin secretion, which is in contrast to type 1 diabetes
models where a high dose of STZ is used to destroy the b-cells. This
model of type 2 diabetes was chosen over others available as it induces
hyperinsulinaemia, mild hyperglycaemia, adiposity and diastolic dysfunc-
tion,7,26,27 thereby mirroring the human disease, yet avoiding extreme
hyperglycaemia and genetic manipulation present in other models.29 On
day 40, control and diabetic rats had fasting blood collected from the sa-
phenous vein to confirm hyperinsulinaemia and hyperglycaemia (blood
glucose measured by Accu-check Aviva blood glucose testing system
and plasma insulin concentrations measured by ELISA, R&D systems).
On day 42, rats were terminally anaesthetized using an intraperitoneal in-
jection of sodium pentobarbital (150 mg/kg bodyweight, Euthatal).
Hearts were excised for perfusion and blood was collected for analysis
of plasma non-esterified fatty acids (NEFA).
2.2 Isolated heart perfusion
Hearts were perfused at a constant pressure of 100 mmHg and an end-
diastolic pressure of 4–8 mmHg. Hearts were perfused with Krebs-
Henseleit buffer containing 11 mM glucose and 1.5% (w/v) fatty acid-free
bovine serum albumin bound to 0.4 mM palmitate at 37 C. Hearts were
initially perfused in normoxia for 20 min by gassing the buffer with 95%
O2 and 5% CO2 to give an oxygen partial pressure (PO2) of
413 ± 15 mmHg. Following normoxia, hearts were made acutely hypoxic
by replacing the gas with 95% N2 and 5% CO2 to decrease the PO2 to
90 ± 10 mmHg for 32 min, followed by reoxygenating the buffer with
95% O2 and 5% CO2 for a further 20 min. Cardiac function was meas-
ured using a fluid-filled PVC balloon inserted into the left ventricle, at-
tached to a bridge amplifier and PowerLab data acquisition system
(ADInstruments). Left ventricular developed pressure was determined
as peak systolic minus end-diastolic pressure, and rate pressure product
(RPP) was the multiple of developed pressure and heart rate. Functional
data were averaged over the last 5 min at the end of normoxia, hypoxia,
and reoxygenation.
2.3 Sulfo-N-succinimidyl oleate
N-hydroxysulfosuccinimide sodium salt was synthesized according to
the protocol of Staros.30 N-hydroxysulfosuccinimide sodium salt
(2 mM), dicyclohexylcarbodiimide (2.2 mM), and oleic acid (4 mM) were
dissolved in dimethylformamide overnight at room temperature, fol-
lowed by stirring for 3 h at 4 C. The product was filtered, washed three
times with dimethylformamide, and sulfo-N-succinimidyl oleate (SSO)
was precipitated from the solution using 20 volumes of ethyl acetate,
filtered, and stored under vacuum in a desiccator. Following optimization



























































































of dose and time to effect, a final concentration of 0.5 mM SSO (dis-
solved in 200 mL DMSO) was added to the perfusion buffer. SSO was
added 4 min prior to the induction of hypoxia and recirculated through-
out the hypoxia-reoxygenation period. Hearts perfused with SSO were
freeze-clamped at the end of reoxygenation.
2.4 Metabolic rates and tissue analysis
For measurement of glycolytic rates, buffer was supplemented with 0.2
lCi.mL-1 [5-3H]-glucose.31 For measurement of palmitate oxidation
rates, buffer was supplemented with 0.2 mCi.mL-1 [9,10-3H] palmitate.31
Lactate efflux rates were measured in timed aliquots using lactate de-
hydrogenase. Metabolic rates were calculated during normoxia, hypoxia
and reoxygenation, from perfusate samples collected at 4-min intervals
for a minimum of five linear data points. In three separate groups, hearts
were freeze-clamped on the cannula at the end of normoxia, following
normoxia-hypoxia, or following normoxia-hypoxia-reoxygenation.
Glycogen content was determined by the conversion of glycogen to gly-
cosyl units, which were assayed using amyloglucosidase. Triglyceride
content was measured following Folch extraction.32 Pyruvate dehydro-
genase (PDH) activity was measured in the active form according to the
protocol of Seymour and Chatham.33 PDH activity was measured as a
surrogate marker for glucose oxidation, as this pathway could not be
measured with the 3H-glucose label.
2.5 Metabolomics
In brief, metabolites were extracted using methanol/chloroform from
50 mg wet weight of powdered, frozen heart tissue.34 The organic and
aqueous fractions were separated by the addition of water and chloro-
form. The aqueous layer was analysed subsequently for metabolomics.
Mass spectrometry was performed on an AB Sciex 5500 (Warrington,
UK) coupled to an Acquity ultra performance liquid chromatography
(UPLC) system from Waters Ltd (Atlas Park, Manchester, UK). Part of
the aqueous extract was dissolved in 70:30 acetonitrile: water containing
20 mM deoxy-glucose 6 phosphate and 20 mM [U-13C,15N] glutamate as
internal standards. For chromatography of nucleotides the strong mobile
phase was 100mM ammonium acetate, the weak mobile phase was
acetonitrile and the LC column used was the ZIC-HILIC column from
Sequant (100 2.1 mm, 5 mm). Metabolites were quantified using pre-
defined mass transitions on the mass spectrometer in positive ion mode.
For the analysis of Krebs cycle intermediates the sample from the above
analysis was recovered and analysed in a second UPLC chromatography
assay with the mass spectrometer in negative ion mode. The strong mo-
bile phase was 10 mM ammonium acetate with 0.05% ammonium hy-
droxide and the weak mobile phase was acetonitrile, and the LC column
used was a BEH amide HILIC column (100 2.1 mm, 1.7 mm; Waters
Ltd). Compound specific parameters such as cone voltage, collision en-
ergy, and mass transitions were used for quantification of the metabol-
ites. For the analysis of amino acids, the remaining aqueous sample was
dried under nitrogen and derivatized with 3M HCl in BuOH for 15 min
at 65C. After further drying, the sample was reconstituted in 9:1 0.1%
formic acid in water/acetonitrile. For chromatography, the strong mobile
phase used for analysis was acetonitrile and the weak mobile phase was
0.1% formic acid in water, and a HSS T3 column (100 2.1 mm, 1.7 mm)
from Waters Ltd was used. Again, cone voltage, collision energy and
mass transitions were optimized for each metabolite for quantification.
Data are expressed in arbitrary units as the area ratio of metabolite peak
relative to the internal standard, normalized to the protein content. In
total, 76 metabolites were identified and quantified per heart.
2.6 Western blotting
For western blotting, protein lysates were prepared from frozen tis-
sue, protein was loaded onto SDS-PAGE gels and separated by elec-
trophoresis.35 Even protein loading and transfer were confirmed by
normalizing to loading controls, either cyclophilin B, or ponceau
staining. For measurement of sarcolemmal transporters, separation
of the sarcolemmal membrane fraction from intracellular endosomes
was carried out according to the established method of Luiken et al.36
Differential centrifugation was used to separate the membrane frac-
tions, and the different fractions were analysed by western blotting
for FAT/CD36 and GLUT4. As described previously, sarcolemmal
fractions had three-fold enrichment of NaþKþ-ATPase protein levels,
whereas microsomal fractions had nine-fold enrichment of Rab4 pro-
tein levels.37 Bands were quantified using UN-SCAN-IT gel software
(Silk Scientific, USA), and all samples were run in duplicate on separ-
ate gels to confirm results.
2.7 Statistics
Results, presented as means ± SEM, were considered significant at
P < 0.05 (SPSS Statistics 18 and GraphPad Prism). Data are presented as
scatter graphs, with n numbers displayed on graphs. Baseline function
and metabolism were compared between control and diabetic hearts
using an unpaired t-test, and characterization of the SSO effect in control
hearts were compared by paired t-test. Metabolomic data were com-
pared using a two-way ANOVA (two factors being diabetic status and
oxygen level). Cardiac function and metabolism with SSO treatment
were compared within the same oxygenation status, using a two-way
ANOVA (two factors being diabetes and drug). Post-hoc comparisons
were made using Tukey test with corrections made for multiple
comparisons.
3. Results
3.1 Characterization of type 2 diabetic rats
There were no significant differences in body weights (377 ± 7 g con-
trol vs. 393 ± 9 g diabetic rats) or in heart weights (1.40 ± 0.03 g con-
trol vs. 1.46 ± 0.03 g diabetic rats) between groups. Epididymal fat
pad weight, a marker of adiposity, was increased by 64% in diabetic
rats compared with controls (5.3 ± 0.3 g vs. 8.7 ± 0.5 g in control and
diabetic rats, respectively, P< 0.05). Fasting blood glucose concentra-
tions were increased by 26% from 5.1 ± 0.3 mmol/L in control rats to
6.4 ± 0.6 mmol/L in diabetic rats (P< 0.05), and fasting plasma insulin
concentrations were increased 2.7-fold from 59 ± 5 pmol/L in control
rats to 163 ± 29 pmol/L in diabetic rats (P < 0.05). Plasma NEFA con-
centrations in the fed state were increased by 83% from 0.06 ±
0.01 mmol/L in control rats to 0.11 ± 0.01 mmol/L in diabetic rats
(P< 0.05).
There were no differences in contractile function in type 2 diabetic
hearts compared with control hearts during baseline normoxic perfusion
(Figures 1 and 6). Glycolytic rate was 53% lower and myocardial glycogen
concentration was decreased by 32% in diabetic hearts compared with
controls (Figure 1). In contrast, fatty acid oxidation rate was increased by
37%, acetyl CoA level was 2.5-fold higher, and free carnitine was 50%
lower in diabetic hearts compared with controls, but with no significant
difference in myocardial triglyceride concentration. Metabolic changes in
the diabetic heart are associated with increased PPARa transcriptional ac-
tivity,38,39 as PPARa targets PDH kinase 4 (PDK4), medium chain acyl co-






..enzyme A dehydrogenase (MCAD), and uncoupling protein 3 (UCP3)
were all significantly increased in the diabetic heart. In line with flux meas-
urements and PPARa activation, whole tissue level of the fatty acid trans-
porter FAT/CD36 was increased by 38%, and sarcolemmal content of
FAT/CD36 was increased by 26% in diabetic hearts compared with con-
trol hearts. In contrast, whole tissue level of the glucose transporter
GLUT4 was decreased by 46%, and sarcolemmal content of GLUT4 was
decreased by 72% in diabetic hearts compared with controls.
Figure 1 Cardiac function and substrate metabolism in control and diabetic hearts under normoxic baseline perfusion. *P< 0.05 vs. control. Acetyl CoA
and free carnitine expressed as peak area ratio, relative to internal standard.





































































..3.2 Infusion of the FAT/CD36 inhibitor,
SSO, into control hearts rapidly modified
metabolism without compromising
function
We questioned whether SSO, an inhibitor of FAT/CD36, would rapidly
decrease fatty acid metabolism and promote glycolysis in the perfused
heart, without having deleterious effects on function. We optimized the
protocol in aerobically perfused control hearts, and found that 0.5 mM
SSO decreased fatty acid oxidation rate by 28% and increased glycolytic
rate by 43%, occurring within minutes of SSO addition (Figure 2). This
metabolic effect of SSO occurred without compromising cardiac func-
tion, with no change in RPP (Figure 2), heart rate (279 ± 11 vs. 287 ± 9
bpm before and after SSO infusion, respectively) and developed pres-
sure (132 ± 7 vs. 125 ± 6 mmHg before and after SSO infusion, respect-
ively). No additional decrease in fatty acid oxidation was seen with a
higher dose of SSO, and we confirmed that the DMSO-vehicle was not
affecting fatty acid metabolism (see Supplementary material online,
Tables S1 and S2).
3.3 Inhibition of FAT/CD36 in diabetic
hearts normalized substrate metabolism
and prevented lipid overload following
hypoxic stress
It has long been recognized that diabetic hearts do worse functionally
when challenged with stress, and that abnormal metabolism plays a key
role in this dysfunction. Given that diabetic hearts have elevated sarco-
lemmal FAT/CD36 and increased fatty acid metabolism, we questioned
whether moderate inhibition of FAT/CD36 with SSO would show bene-
fit for the diabetic heart during exposure to hypoxic stress. Therefore,
we infused SSO into diabetic and control hearts 4 min prior to acute
hypoxia, and recirculated it throughout the subsequent reoxygenation
period. Hypoxia significantly decreased the fatty acid oxidation rate, with
no difference between control and diabetic hearts, with or without SSO
present (Figure 3), demonstrating this metabolic response was likely
driven by low oxygen availability. In contrast, following reoxygenation
SSO treatment of diabetic hearts normalized the fatty acid oxidation
rate back to that found in control hearts, decreasing fatty acid oxidation
by 29% compared with untreated diabetic hearts. This improvement in
fatty acid oxidation at reoxygenation occurred concomitantly with an
improvement of myocardial triglycerides. Whereas in untreated diabetic
hearts myocardial triglyceride concentration was 73% greater than in
control hearts at reoxygenation, this was restored to control levels by
SSO infusion. Hypoxia significantly increased glycolytic rates in all hearts,
however, in diabetic hearts glycolytic rate remained 55% lower than in
control hearts, demonstrating impaired upregulating of glycolysis in re-
sponse to hypoxia. This was not due to impaired p-AMPK activation and
AMPK signalling in diabetic hearts during hypoxia (see Supplementary
material online, Figure S1). SSO treatment of diabetic hearts was able to
increase glycolytic rate by 46% compared with untreated diabetic hearts
during hypoxia (Figure 3). However, SSO had no significant effect on
glycolytic rate at reoxygenation or on myocardial glycogen concentra-
tion, SSO increased PDH activity in diabetic hearts by 53%, so that it was
no longer significantly different to controls. This SSO-mediated increase
in PDH flux in diabetic hearts was accompanied by a significant decrease
in lactate efflux rate following reoxygenation, indicating that more pyru-
vate was being oxidized in the mitochondria following SSO treatment of
diabetic hearts. Glucose-1-phosphate level was restored to control lev-
els by SSO-treatment of diabetic hearts.
3.4 FAT/CD36 inhibition modulated Krebs
cycle intermediates in diabetic hearts,
predominantly within the second span of
the cycle
Next, we questioned whether metabolic intermediates were being
changed by hypoxic stress, and whether these changes were abrogated
following reoxygenation by SSO. In normoxia, there were no significant
differences in any Krebs cycle intermediate between control and diabetic
hearts (Figure 4). In response to hypoxia-reoxygenation, intermediates
within the first span of the Krebs cycle, namely citrate, aconitate, and iso-
citrate, were decreased in control and diabetic hearts, with citrate signifi-
cantly lower in diabetic hearts at reoxygenation, and isocitrate
significantly lower in diabetic hearts after hypoxia. Sequential intermedi-
ates in the second span of the Krebs cycle, namely succinate, fumarate,
and malate, were increased in control hearts, by between two- and five-
fold, following hypoxia. There were significant interactions for succinate,
fumarate, and malate between diabetes and oxygenation, demonstrating
that in diabetic hearts these intermediates were differently modified by
hypoxia-reoxygenation. In diabetic hearts, succinate, fumarate, and mal-
ate were 28–54% lower following hypoxia compared with control
hearts. The total FAD pool (FAD and FADH2), essential for the oxida-
tion of succinate to fumarate by succinate dehydrogenase, (in addition to
branched chain amino acid catabolism and fatty acid oxidation), was se-
lectively depleted by 31% in diabetic hearts following reoxygenation
compared with controls. This decrease in the FAD total pool in diabetic
hearts occurred independently of changes in NAD total pool, phospho-
creatine or ATP, when compared with control hearts (Table 1).
SSO treatment of diabetic hearts had an anaplerotic effect on selective
steps within the Krebs cycle (Figure 5). SSO treatment of diabetic hearts
increased Krebs cycle intermediates in the second span of the cycle,
Figure 2 Substrate metabolism and cardiac function in control normoxic perfused hearts, before and after infusion of 0.5 mM SSO. *P< 0.05 vs. control
without SSO.












..doubling the level of fumarate and increasing oxaloacetate by 61% com-
pared to untreated diabetic hearts. The total FAD pool, which was
depleted at reoxygenation in diabetic hearts, was significantly increased
by 67% by SSO treatment of diabetic hearts. Citrate level was marginally
increased, so that it was no longer significantly different to controls
(Figure 5).
A number of amino acids were modulated in diabetic hearts exposed
to hypoxia/reoxygenation (Table 1 and see Supplementary material
online, Table S3). Lysine, aspartate, and asparagine were increased in dia-
betic hearts in normoxia, leucine, isoleucine, and phenylalanine were
decreased following hypoxia, and histidine and phenylalanine were
decreased following reoxygenation in diabetic hearts compared with
controls. Markers of the antioxidant system, reduced and oxidized gluta-
thione, were not different between controls and diabetic hearts. None
of these metabolites were modulated by SSO treatment (see
Supplementary materials online, Table S4).
Figure 3 Substrate metabolism in control and diabetic hearts, with and without FAT/CD36 inhibitor SSO, during hypoxia and reoxygenation. *P< 0.05
vs. control under same oxygen condition, #P< 0.05 vs. diabetic, WP< 0.05 vs. controlþ SSO. Glucose-1-phosphate expressed as peak area ratio, relative to
internal standard. Fatty acid oxidation and glycolytic rate n numbers are the same in hypoxia and reoxygenation.















..3.5 Inhibition of FAT/CD36 corrected
cardiac dysfunction in diabetes
Finally, we questioned whether the beneficial metabolic effects of SSO
would translate to a functional benefit during hypoxia and reoxygenation
in the diabetic heart (Figure 6). At reoxygenation, RPP and developed
pressure were significantly lower (P< 0.05) in both control and diabetic
hearts compared with in normoxia, whereas other parameters returning
to their normoxic levels. SSO had an overall beneficial effect on RPP in
diabetic hearts both during hypoxia and reoxygenation. In diabetic
hearts, SSO treatment increased RPP during hypoxia by 60% and during
reoxygenation by 32% compared with untreated diabetic hearts. This re-
sulted in average percentage recovery of 73% in control hearts, 67% in
control hearts treated with SSO, 55% in diabetic hearts, and 69% in dia-
betic hearts treated with SSO. Following SSO treatment end-diastolic
pressure was normalized in diabetic hearts during hypoxia, and was no
longer significantly different to control hearts. SSO treatment signifi-
cantly increased heart rate in diabetic hearts during hypoxia, and follow-
ing reoxygenation restored heart rate in diabetic hearts to control levels.
SSO had no significant effects on developed pressure, positive or nega-
tive dP/dt max, or coronary flow rates in any group.
Figure 4 Myocardial levels of Krebs cycle intermediates from control and diabetic hearts under normoxia (Nx), hypoxia (Hx), and reoxygenation (Rx).
*P< 0.05 vs. control under same oxygen condition, #P< 0.05 vs. normoxia within same disease state, WP< 0.05 vs. hypoxia within same disease state. Data
expressed as peak area ratio, relative to internal standard.
















































The type 2 diabetic heart had an abnormal metabolic and functional re-
sponse when challenged with acute hypoxia-reoxygenation. In this study
we demonstrate for the first time that moderate inhibition of FAT/CD36
can be achieved rapidly in the intact perfused heart using SSO. During
hypoxic stress, SSO can promote glycolysis, decrease myocardial trigly-
ceride deposition, and increase PDH flux in diabetic hearts. In addition,
using metabolomics we were able to identify unexpected changes in
metabolic intermediates, which demonstrated that SSO treatment had
an anaplerotic effect to increase Krebs cycle intermediates within the se-
cond span of the cycle. These metabolic changes culminated in improved
cardiac function during hypoxia and after reoxygenation, restoring func-
tion to levels found in control hearts. Thus, pharmacological inhibition of
FAT/CD36 provides a mechanism to improve substrate metabolism,
prevent lipid overload and restore cardiac function in diabetes.
SSO was used in the initial identification of FAT/CD36 as the plasma
membrane protein responsible for fatty acid uptake,40 and has subse-
quently been used to define the functional significance of FAT/CD36.41–44
By administering SSO to the perfused heart we addressed two ques-
tions: whether pharmacological inhibition of FAT/CD36 was feasible
and, secondly, whether rapidly suppressing fatty acid metabolism is suf-
ficient to restore cardiac function following stress. Genetic studies
have shown that FAT/CD36 deficiency can rescue cardiac lipotoxicity
associated with PPARa overexpression,17 thus, translation of a genetic
finding to a therapeutic angle was of great interest. As therapeutic
proof of concept, incubating primary cardiomyocytes with an antibody
raised to FAT/CD36 improved sarcomere shortening following expos-
ure to a high palmitate culture media.45 In this study, we demonstrated
that SSO infusion rapidly restored fatty acid oxidation rates in diabetic
hearts back to control levels. In addition, SSO had the added advantage
of also preventing the accumulation of intracellular triglycerides, a
benefit that does not occur with compounds that target mitochondrial
fatty acid oxidation, such as etomoxir, where fatty acid import and
esterification may continue unhindered.16 One potential concern was
that the degree of FAT/CD36 inhibition may be too great, which would
result in substrate starvation and contractile dysfunction given that
fatty acids are the main fuel for ATP generation. However, we have
shown that SSO can be used to induce small changes in metabolism
without compromising cardiac function.
In diabetic hearts, functional defects only arose when the myocardium
was stressed by hypoxia, and could be reversed in minutes by changing
metabolism, demonstrating that the functional deficit was not a fixed ir-
reversible effect of the disease. In diabetic and GLUT4-deficient mice
where glucose metabolism is suppressed, hypoxia induces abnormalities
in electrical activity and action potential duration.46,47 This documented
association between metabolism and electrical activity in the heart may
contribute to the changes in heart rate in our hypoxic diabetic animals
and with acute metabolic therapy. SSO treatment improved end-
diastolic pressure during hypoxia in diabetic hearts, an indicator of im-
proved relaxation and compliance following metabolic modulation.
Glucose uptake and metabolism are regulated by multiple signalling
pathways, both at baseline and in response to stress.22,48 Glycolytic rates
were increased to a much lesser extent in diabetic hearts than controls
in response to hypoxia, which we show was not attributable to abnormal
p-AMPK activation. This raised the question of whether hypoxia had al-
ready reached the maximal glycolytic response in the diabetic heart. We
found this was not the case, and inhibition of FAT/CD36 provided an
additional stimulus to increase glycolytic rates further in diabetic hearts.
This demonstrated that increased fatty acid metabolism was responsible
for suppressing anaerobic metabolism, in accordance with the Randle
cycle,10 and as highlighted by the restoration of PDH activity. That SSO
......................................................... .......................................................... ...........................................................
..............................................................................................................................................................................................................................
Table 1 Metabolic intermediates from control and diabetic hearts following normoxia, hypoxia and reoxygenation
Normoxia Hypoxia Reoxygenation
Control (n5 6) Diabetic (n5 5) Control (n5 5) Diabetic (n5 5) Control (n56) Diabetic (n5 6)
NAD total pool 0.93 ± 0.05 0.96 ± 0.11 0.95 ± 0.05 0.89 ± 0.07 0.82 ± 0.12 0.60 ± 0.05#
Phosphocreatine 36.2 ± 2.5 32.4 ± 4.7 16.3 ± 2.9# 13.3 ± 3.5# 38.9 ± 5.2† 28.5 ± 3.2†
ATP 8.0 ± 0.4 9.2 ± 0.9 5.4 ± 0.9 4.1 ± 0.7# 4.7 ± 1.1# 5.5 ± 0.5#
Adenine 0.013 ± 0.001 0.013 ± 0.002 0.016 ± 0.000 0.013± 0.001* 0.016 ± 0.001 0.011± 0.001*
Acetyl CoA 0.0020 ± 0.0003 0.0050± 0.0007* 0.0013 ± 0.0003 0.0021 ± 0.0003 0.0011 ± 0.0009# 0.0006 ± 0.0002#
Glutathione 0.00070 ± 0.00032 0.00157 ± 0.00126 0.00020 ± 0.00003 0.00018 ± 0.00005 0.00016 ± 0.00003 0.00096 ± 0.00045
Oxidized glutathione 0.202 ± 0.006 0.226 ± 0.015 0.229 ± 0.010 0.229 ± 0.011 0.184 ± 0.014# 0.153 ± 0.011#,†
Leucine 0.072 ± 0.004 0.097 ± 0.012 0.188 ± 0.011# 0.146± 0.012*,# 0.108 ± 0.013† 0.079 ± 0.008†
Isoleucine 0.060 ± 0.005 0.083 ± 0.011 0.170 ± 0.007# 0.135± 0.013*,# 0.088 ± 0.014† 0.060 ± 0.006†
Phenylalanine 0.052 ± 0.004 0.055 ± 0.006 0.080 ± 0.010 0.053± 0.005* 0.076 ± 0.006 0.054± 0.006*
Lysine 0.16 ± 0.01 0.32± 0.04* 0.17 ± 0.02 0.25 ± 0.03 0.22 ± 0.02 0.22 ± 0.02
Aspartate 0.11 ± 0.01 0.16± 0.01* 0.09 ± 0.01 0.14 ± 0.03 0.09 ± 0.01 0.09 ± 0.01#
Asparagine 0.015 ± 0.001 0.027± 0.002* 0.017 ± 0.001 0.018 ± 0.005 0.014 ± 0.002 0.015 ± 0.002
Glutamate 17.6 ± 1.3 19.3 ± 2.9 10.2 ± 0.7# 12.2 ± 0.9# 9.6 ± 1.4# 7.7 ± 0.8#
Glutamine 6.2 ± 0.3 6.6 ± 0.9 4.0 ± 0.3# 4.8 ± 0.1 3.8 ± 0.4# 2.6 ± 0.2#,†
Histidine 0.28 ± 0.01 0.25 ± 0.01 0.25 ± 0.03 0.20 ± 0.02# 0.20 ± 0.02# 0.13± 0.01*,#,†
Alanine 0.19 ± 0.02 0.22 ± 0.06 0.42 ± 0.03# 0.37 ± 0.06 0.16 ± 0.03† 0.11 ± 0.02†
Data expressed as peak area ratio, relative to internal standard.
*P< 0.05 vs. control at same oxygenation (highlighted in bold);
#P< 0.05 vs. normoxia within same disease state;
†P< 0.05 vs. hypoxia within same disease state.





















..did not confer the same benefits to control hearts may be due to meta-
bolic flexibility already being optimal in the healthy heart. Thus, there is
inherent metabolic flexibility in the diabetic heart; but it requires simul-
taneous activation of multiple pathways—via the intrinsic hypoxic re-
sponse, including AMPK signalling, and via extrinsic metabolic
modulation. The combined effects of decreasing fatty acid metabolism
and increasing glucose metabolism by SSO make it difficult to assign
which of these two factors is responsible for improving functional out-
comes in the diabetic heart. Given the reciprocal regulation between
metabolic pathways, any process that changes one of these pathways
will always modify the other, and, therefore, it is most likely that overall
benefit is gained by the combination of the two.
Metabolomics is a non-hypothesis driven experimental approach,
which allowed us to determine if there were any additional effects of
short-term metabolic modulation, above and beyond those that would
be predicted from traditional studies. Metabolomics identified that the
effect of hypoxia on the Krebs cycle was not uniform, that intermediates
within the first span were depleted, whereas intermediates within the se-
cond span accumulate. The enzymatic steps where these patterns
change are all NAD-dependent dehydrogenase or substrate level phos-
phorylation steps, indicating this profile in hypoxia is likely due to mito-
chondrial redox-dependent regulation. The increase in succinate during
hypoxia is consistent with Chouchani et al.,49 who showed an increase in
succinate during ischaemia. However, in contrast to our findings, they
did not identify changes in other Krebs cycle intermediates, indicating dif-
ferences in the myocardial response to different stressors. Hypoxia is a
less severe stressor for the heart than global ischaemia, as waste product
removal and substrate delivery can still continue, which may account for
Figure 5 Myocardial levels of Krebs cycle intermediates at reoxygenation from control and diabetic hearts, with and without FAT/CD36 inhibitor SSO.
*P< 0.05 vs. control, #P< 0.05 vs. diabetic, WP< 0.05 vs. controlþ SSO. Data expressed as peak area ratio, relative to internal standard.
FAT/CD36 inhibition improves the diabetic heart 745
Figure 6 Cardiac function in control and diabetic hearts, with and without FAT/CD36 inhibitor SSO, during hypoxia and reoxygenation. *P< 0.05 vs.
control, #P< 0.05 vs. diabetic. End diastolic pressure n numbers as per developed pressure.



























































































these different responses. Diabetes decreased a number of intermedi-
ates within the Krebs cycle, namely citrate, isocitrate, succinate, fumar-
ate, and malate. In agreement with our findings, Banke et al.50
demonstrated abnormal Krebs cycle flux in diabetic hearts only when
stressed by ischaemia. Of interest was the increase in fumarate, oxaloa-
cetate and the FAD pool with SSO treatment of diabetic hearts, demon-
strating an additional anaplerotic benefit from metabolic therapy in
diabetes.
The current findings demonstrate beneficial metabolic and func-
tional effects of SSO for the diabetic heart, and future in vivo studies
are warranted. Any changes induced by acute SSO in this study were
immediate via existing proteins, whereas chronic studies may exert
additional effects via transcriptional/translational changes within
the heart. Potentially SSO may also reduce the deleterious effects
of intracellular lipids associated with insulin resistance and cell
death.51,52 However, there are a number of critical hurdles to over-
come, such as systemic delivery affecting metabolism and function of
other tissues, such as skeletal muscle and adipose, as well as unknown
longer term effects on cardiac function.
In conclusion, type 2 diabetes impairs the metabolic and functional re-
sponse to hypoxia-reoxygenation stress. Pharmacological inhibition of
the sarcolemmal fatty acid transporter, FAT/CD36, provides a rapid
mechanism to suppress fatty acid oxidation and promote glycolysis.
Targeting the primary transport step in the pathway also prevented ex-
cessive lipid deposition and rebalanced Krebs cycle intermediates result-
ing in improved cardiac function in diabetic hearts following hypoxic
stress.
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